BioMarin Pharma (BMRN) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
BioMarin (BMRN) PT Lifted to $87 at Jefferies Posts Q3
October 24, 2014 8:24 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and boosted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $87.00 (from $84.00) following better-than-expected product sales.
Yang commented, "Better-than-expected 3Q products sales led to ~1-3% upside revision to FY14 revenue guidance (+28-29% y/y).... More
